Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sumatriptan succinate, quantity: 139.98 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide - sumatrip tablets are indicated for the acute relief of migraine attacks with or without aura.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sumatriptan succinate, quantity: 69.99 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hypromellose; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; triacetin; iron oxide red - sumatrip tablets are indicated for the acute relief of migraine attacks with or without aura.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 15 mg - tablet, film coated - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; crospovidone; titanium dioxide; polysorbate 80; macrogol 400; indigo carmine aluminium lake - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 15 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; magnesium stearate; microcrystalline cellulose; lactose monohydrate; hypromellose; titanium dioxide; polysorbate 80; macrogol 400; indigo carmine aluminium lake - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; lactose monohydrate; microcrystalline cellulose; crospovidone; hypromellose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.